| First Author | Zhong X | Year | 2024 |
| Journal | J Exp Med | Volume | 221 |
| Issue | 6 | PubMed ID | 38625151 |
| Mgi Jnum | J:349474 | Mgi Id | MGI:7623096 |
| Doi | 10.1084/jem.20232132 | Citation | Zhong X, et al. (2024) Viable mutations of mouse midnolin suppress B cell malignancies. J Exp Med 221(6) |
| abstractText | In a genetic screen, we identified two viable missense alleles of the essential gene Midnolin (Midn) that were associated with reductions in peripheral B cells. Causation was confirmed in mice with targeted deletion of four of six MIDN protein isoforms. MIDN was expressed predominantly in lymphocytes where it augmented proteasome activity. We showed that purified MIDN directly stimulated 26S proteasome activity in vitro in a manner dependent on the ubiquitin-like domain and a C-terminal region. MIDN-deficient B cells displayed aberrant activation of the IRE-1/XBP-1 pathway of the unfolded protein response. Partial or complete MIDN deficiency strongly suppressed Emu-Myc-driven B cell leukemia and the antiapoptotic effects of Emu-BCL2 on B cells in vivo and induced death of Sp2/0 hybridoma cells in vitro, but only partially impaired normal lymphocyte development. Thus, MIDN is required for proteasome activity in support of normal lymphopoiesis and is essential for malignant B cell proliferation over a broad range of differentiation states. |
